Many of the macroeconomic challenges that halted biotech IPO activity in 2022 and 2023 have begun to subside and the capital markets are expected to continue improving. While biotech IPOs might take a little while to get back to pre-pandemic levels, there's reason to be optimistic especially since the Fed is poised to lower rates in the second half of 2024. Our panel will dive into lessons learned from past IPOs and how early-stage biotech’s can avoid common pitfalls.